Singapore, 12 July 2022: A novel therapy to treat rare gastrointestinal stromal tumours (GIST) has been accepted for evaluation by Singapore’s Health Sciences Authority.
- Welcome to Specialised Therapeutics
-
SE Asia (HQ)
+65 3158 9910
-
Australia
1300 798 820
-
New Zealand
+64 9801 0299
GIST - Specialised Therapeutics
March 29, 2022
New Early Breast Cancer Drug to Reduce Risk of Recurrence or Death Now Available in Malaysia
Singapore, 29 March 2022: A NEW drug shown to significantly reduce the risk of cancer recurrence or death in an aggressive form of breast cancer is now available in Malaysia. The drug, NERLYNX® (neratinib) is an oral medication taken for 12 months by women who have been diagnosed with early stage HER2-positive (HER2+) breast cancer and who have received prior trastuzumab-based therapy.
November 15, 2021
‘Great Relief’ for Australian Patients with New Therapy to Treat Rare GIST Cancers Listed on PBS
QINLOCK® (ripretinib) now PBS listed for Australian patients QINLOCK is the first new reimbursed therapy to treat advanced GIST in more than a decade Leading Australian oncologist says the listing will help to “buy patients more time” Data shows QINLOCK reduces risk of disease progression by 85%1, 2 14 November, 2021: AUSTRALIAN cancer patients